Javier Blanco Clin. Biochem., Ph.D.

Javier Blanco

Javier Blanco
Clin. Biochem., Ph.D.

Associate Professor

Contact Information
470 Kapoor Hall
Buffalo, New York 14214-8033
Phone: (716) 645-4820
jgblanco@buffalo.edu



Professional Summary:

Research focus is the improvement of cancer chemotherapy by understanding the factors that contribute to interindividual variability in drug response.

Dr. Blanco‘s goal is to perform translational research using a combination of approaches based on a) the analysis of biological samples from selected
populations, and b) the use of informative laboratory models.

A project in Dr. Blanco‘s laboratory is related to the understanding of the factors that govern interindividual variability in the metabolism and disposition of the anthracyclines doxorubicin and daunorubicin. It is possible that specific sequence variations in genes associated with the metabolism and disposition of anthracyclines may impact the risk of cardiotoxicity in some individuals. Our efforts are focused on the discovery and characterization of novel single-nucleotide polymorphisms in a family of genes involved in the metabolism of anthracyclines in liver, heart and different types of tumors (e.g. breast and lung cancer). We are investigating the extent of DNA sequence variation in these selected gene candidates among normal individuals from different ethnic groups. We will study genotype-phenotype correlations by using paired tissue-DNA-RNA samples available from my collaborators from the Pharmacogenetics of Anticancer Agents Research group, and from the Roswell Park Cancer Institute. We will expand our studies to characterize the functional effect of the genetic variants by using different in-vitro and in-vivo models (e.g. cultures of hepatocytes,cardiomyocytes, transgenic mice).

Our findings are being translated into informative case-control epidemiological studies. For example, we are analyzing the distribution of candidate polymorphisms in identically treated patients who have vs. have not developed congestive heart failure (CHF) after anthracycline treatment for childhood cancer. In the future, individualizing the dosing of anthracyclines based on genetic characteristics might minimize the occurrence of adverse effects.

Education and Training:

  • National University of Cordoba, Argentina
  • St. Jude Children‘s Research Hospital
  • PhD, National University of Cordoba, Argentina



Presentations:

  • "Molecular Determinants for Anthracycline-Related Cardiotoxicity in Survivors of Pediatric Cancers" (2017)
  • "Organizer, Dialogue and Debate Session Stem-Cell Derived Cell Lines: Platforms to Evaluate Drug Metabolism and Transport" 2016 AAPS Annual Meeting and Exposition (2016)
  • "Pharmacogenetics: Clinical Implementation and Regulatory Considerations" 1rst National Scientific Congress on Professional Biochemistry (2016)
  • "Pharmacogenomic Determinants Associated to the Cardiotoxicity of Anthracycline Drugs" XVI Latin-American Congress of Genetics (2016)
  • "Post graduate level course in Pharmacogenetics. Module: Cancer Pharmacogenetics" Faculty of Chemistry, University of the Republic, Montevideo, Uruguay (2016)
  • "The Pharmacogenomics of Anthracycline-related Cardiotoxicity in Survivors of Pediatric Cancers" (2016)
  • "Identification of Pharmacogenetic Determinants in Cardio-Oncology" VI Ibero-American Congress of Pharmaceutical Sciences/XLVII Meeting of the Argentinian Society of Experimental Pharmacology/III South American Congress of Biopharmacy and Pharmacokinetics (2015)
  • "The Pharmacogenetics of Anthracycline-Based Therapies in Survivors of Pediatric Cancers" (2015)
  • "Pinpointing Molecular Determinants for the Cardiotoxicity Associated to Anticancer Therapies" (2015)
  • "Pharmacogenetic Insights into Anthracycline-Related Cardiotoxicity" (2015)
  • "Basic Notions on Clinical Pharmacogenetics: Recent Developments and Clinical Utility." Barcelo University: special conference (2014)
  • "Clinical Pharmacogenetics" Post graduate level course in Clinical Pharmacogenetics. National University of Cordoba (2014)
  • "The Pharmacogenetic Bases of Cardio-oncology." Barcelo University: special conference (2014)
  • "Pharmacogenetics of Late Effects in Survivors of Pediatric Cancers (Farmacogenetica en Sobrevivientes de Canceres Pediatricos)" Post-graduate level course "Molecular Bases of Gene Expression and its Impact in Cell Physiology". Department of Clinical Biochemistry, National University of Córdoba (2012)
  • "Trends in Pharmacogenetics: Defining Clinical Utility (Nociones Básicas de Farmacogenética: Desarrollos Recientes y Utilidad Clínica)" Argentinian Food, Drugs, and Medical Technology Administration (ANMAT) (2012)
  • "Pharmacogenetics of Pediatric Cancers. Genetic Determinants of Efficacy and Late Toxicity (Farmacogenética de Cánceres Pediátricos. Determinantes Genéticos de Eficacia y Toxicidad Tardia)" Argentinian Society of Pediatrics (Catamarca‘s Division) and the Committee for Research and Teaching Development (Catamarca‘s Province Central Children‘s Hospital) (2012)
  • "Novel Risk Factors for Anthracycline-related Cardiomyopathy in Pediatric Cancer Survivors. A Report from the Children's Oncology Group." XII Buffalo Pharmaceutics Symposium (2010)
  • "Anthracycline-related cardiomyopathy in childhood cancer survivors and associations with polymorphisms in the carbonyl reductase genes: A Children's Oncology Group study" Annual Meeting of the American Society of Clinical Oncology (2010)
  • "Pharmacogenetics of Human CBR1 in Livers from Black and White Donors" Annual Meeting of the American Association of Pharmaceutical Scientists (2008)
See all (9 more)

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

470 Kapoor Hall
Buffalo, New York 14214-8033
Phone: (716) 645-4820
jgblanco@buffalo.edu